Cripto-1 and OCT4, expressed in stem cells and cancers, play important roles in tumorigenesis. Here, we demonstrate that Cripto-1 expression is regulated by OCT4 in human embryonic carcinoma NCCIT cells. The endogenous expression of Cripto-1 and OCT4 is significantly reduced during differentiation. Cripto-1 expression is increased by OCT4 overexpression, but decreased by shRNA-mediated OCT4 knockdown. OCT4 overexpression significantly activates Cripto-1 transcriptional activity. A 5 0 -upstream minimal promoter sequence in the gene-encoding Cripto-1 is significantly activated by OCT4 overexpression. Mutation of the putative OCT4-binding site abolishes OCT4-mediated activation of the Cripto-1 promoter. The OCT4 transactivation domains mediate transcriptional activity of the Cripto-1 minimal promoter through direct interaction. Taken together, OCT4 plays an important role as a transcriptional activator of Cripto-1 expression in NCCIT cells.
Testicular germ cell tumors (GCTs) develop heterogeneously and are subdivided into seminomas and nonseminomas. Seminomas resemble undifferentiated primitive germ cells. In contrast, embryonal carcinoma (EC) cells are the stem cell population of the nonseminomas and a malignant counterpart to embryonic stem (ES) cells. Therefore, EC cells not only have self-renewal and differentiation potentials but also are highly malignant [1] [2] [3] [4] . Gene expression patterns of human ES cells show many similarities with the human EC cells, suggesting that they are necessary for maintenance of a pluripotent or undifferentiated phenotype. Furthermore, it could be possible to examine the function of those candidate genes in converting ES cells to their malignant EC counterparts by manipulating those genes in ES cells [5] .
Among those candidates, octamer-binding transcription factor 4 (OCT4) is an important stem cell mediator belonging to the POU (Pit-Oct-Unc) domain family characterized by binding to an octameric sequence motif (ATGCAAAT) in order to activate downstream target gene expression [6] . OCT4, expressed in both ES and EC cells, is tightly regulated to maintain the characteristics of pluripotent stem cells, as either high or low expression may induce differentiation [5, [7] [8] [9] . OCT4 is also expressed in a variety of solid tumors as well as in GCTs and is involved in tumorigenesis of cancer stem cells [10] [11] [12] [13] [14] [15] [16] . Therefore, deregulation and dysfunction of OCT4 may affect its oncogenic potential in a variety of cancers.
ES cells share several signaling pathways with cancer stem cells, also known as tumor-initiating cells [17, 18] . Therefore, identifying molecular markers involved in their shared signaling pathways is critical to understand tumorigenic processes of stem cells. Human Plasmid DNA and short hairpin RNA against OCT4 constructs
The human Cripto-1 promoter region (À3320 to À1; nucleotide position relative to the translational start site as +1) was amplified by PCR using genomic DNA from human lymphocytes and cloned into the pGL3-basic reporter vector (Promega, Madison, WI, USA). Various Cripto-1 promoter deletion derivatives (À2569-Luc, À2104-Luc, À1718-Luc, À1048-Luc, À500-Luc, À100-Luc) were generated using the À3320-Luc construct as a template. A core sequence of putative OCT4-binding site within Cripto-1 minimal promoter (À100-Luc) was replaced with SacI restriction sequence (GAGCTC) using the QuickChange site-directed mutagenesis method (Stratagene, La Jolla, CA, USA). The expression vectors for human OCT4 full-length (FL) and deletion variants [N-terminal domain (NTD) to POU DNA-binding domain (DBD), DBD, DBD to C-terminal domain (CTD)] were used, as previously reported [30, 31] . All cloned PCR products and reporter plasmids were verified by sequencing.
To interfere with OCT4 expression, the OCT4 short hairpin RNA (shRNA) expression vector (pGSH1-GFP-OCT4 shRNA) was used, as previously described [31] . Briefly, two double-stranded oligonucleotides were generated by annealing 5 0 -GATCCGCGATCAAGCAGCGACTATGAAGCTTG ATAGTCGCTGCTTGATCGCTTTTTTGGAAGC-3 0 (sense) and 5 0 -GGCCGCTTCCAAAAAAGCGATCAAGCAGCGAC TATCAAGCTTCATAGTCGCTGCTTGATCGCG-3 0 (antisense) and were ligated into BamH1 and Not1-digested pGHS1-GFP shRNA expression vector (Genlantis, San Diego, CA, USA). OCT4 sense and antisense sequences are underlined and hairpin loop structure with HindIII sequence is marked in italics. The pGSH1-GFP-luciferase shRNA vector (Genlantis) was used for a control.
Transient transfection, RNA preparation, and qRT-PCR NCCIT cells were transfected with pGSH1-GFP-OCT4 shRNA or FLAG-tagged OCT4 expression vectors using ViaFect TM transfection reagent (Promega) according to the manufacturer's protocol. pGSH1-GFP-luciferase shRNA and FLAG-tagged pcDNA3.1 + vectors were used as controls. Total RNAs were prepared from undifferentiated, differentiated, and transfected NCCIT cells using TRizol reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions. RNA samples were synthesized to complementary DNA (cDNA) using AccuPower RT PreMix kit (Bioneer, Daejeon, South Korea). For qRT-PCR, cDNAs were amplified with PCR SensiFAST SYBR No-ROX kit (Bioline, Luckenwalde, Germany). The forward and reverse primers were as follows: Cripto-1(89 bp), 0 -GATGGAGTTGAAGGTAGTTTCGTG -3 0 (reverse). b-actin cDNA was amplified from all samples as a normalizing control. Relative quantification of the expression levels was determined using the 2 ÀDDCt method [32] .
Western blot analysis
For western blot analysis, NCCIT cells were transfected with pGSH1-GFP-OCT4 shRNA or FLAGtagged OCT4 expression vectors using ViaFect TM transfection reagent (Promega) according to the manufacturer's protocol. pGSH1-GFP-luciferase shRNA and FLAG-tagged pcDNA3.1 + vectors were used as controls. NCCIT cells, which were undifferentiated, differentiated, and transfected with FLAG-tagged OCT4 and OCT4 shRNA expression vectors, were lysed with RIPA lysis buffer [150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Luciferase reporter assays
NCCIT and HEK293T cells were transfected by ViaFect TM transfection reagent (Promega) according to the manufacturer's protocol. The reporter assays were performed in duplicate in three or more independent experiments. Luciferase activities of reporter plasmids were normalized to bgalactosidase activity of a cotransfected internal control plasmid (pcDNA3.1/hygro/LacZ; Invitrogen). The pGL3-basic vector was used as a control.
Electrophoretic mobility shift assay (EMSA) 
Chromatin immunoprecipitation (ChIP) analysis
ChIP assay was performed as described previously [33] , with a minor modification. The chromatin DNA was prepared from undifferentiated NCCIT cells using swelling buffer (100 mM Tris, pH 8.0, 1. 
Statistical analysis
All experiments were performed independently at least three times. Each independent replicate of real-time PCR and reporter assays was performed in duplicate. Data shown in figures are means AE standard deviations (SD) of over all trials. The data were analyzed by t-test or ANOVA with Duncan's multiple range procedure for multiple comparisons, using the SigmaPlot 11.2 program (Systat Software, San Jose, CA, USA). In all experiments, P < 0.01 and P < 0.05 were considered statistically significant.
Results

Expression analysis of Cripto-1 and OCT4 in NCCIT cells
To find the relationship between expression of Cripto-1 and OCT4 in NCCIT cells, cells were treated with RA to induce differentiation and analyzed using qRT-PCR and western blot (Fig. 1 ). Both mRNA (Fig. 1A) and protein (Fig. 1B ) levels of Cripto-1 and OCT4 significantly decreased following RA-mediated differentiation in a time-dependent manner.
To find a direct transcriptional relationship between Cripto-1 and OCT4, we transiently induced overexpression and shRNA-mediated knockdown of OCT4 in NCCIT cells and performed qRT-PCR and western blot analyses (Fig. 2) . Overexpression of OCT4 significantly elevated the expression of endogenous Cripto-1, whereas OCT4 shRNA-mediated knockdown significantly decreased the expression of endogenous OCT4 and Cripto-1. These data suggest that OCT4 may directly affect Cripto-1 expression in NCCIT cells.
Cripto-1 promoter activity is activated by OCT4 in a dose-dependent manner
To determine the functional relationship between Cripto-1 and OCT4 at the transcriptional level, Cripto-1 promoter-reporter construct (À3320-Luc) (Fig. 3A) . Promoterreporter assays showed that Cripto-1 transcriptional activity was significantly increased by OCT4 expression in a dose-dependent manner (Fig. 3B) , suggesting that OCT4 acts as a potent transactivator in Cripto-1 expression. Next, serial deletion mutant constructs of Cripto-1 promoter (À3320-Luc, À2595-Luc, À2104-Luc, À1718-Luc, À1048-Luc, À500-Luc, and À100-Luc) were cotransfected with OCT4 into NCCIT cells (Fig. 4) . OCT4 overexpression significantly activated the transcriptional activities of the promoter-reporter constructs (À3320-Luc, À2595-Luc, and À2104-Luc). Interestingly, whereas the construct (À500-Luc) dramatically decreased the activity regardless of OCT4 expression, the construct (À100-Luc) recovered the activity to some extent and was significantly activated by exogenous OCT4 overexpression. Therefore, the region from À100 to À1 was designated as the Cripto-1 minimal promoter. These data suggest that strong negative regulatory elements are present or positive elements are absent between À500 and À100, and the minimal promoter (À100 to À1) may contain positive regulatory element(s), including a putative OCT4-binding site. The abundance of OCT4 and Cripto-1 mRNA transcripts was measured using qRT-PCR relative to those of control transfectants. b-actin was used as an internal control for normalization of cDNA content. Data represent the means and SD from three independent experiments performed in duplicate. *P < 0.05, **P < 0.01. (b) Western blotting of OCT4 and Cripto-1 protein expression following overexpression of OCT4 in NCCIT cells using anti-OCT4 and anti-Cripto-1 antibodies. b-actin was used as an internal control for normalization of total protein content. The blots were quantitated using densitometry with the ImageJ software program. **P < 0.01. (B) shRNA-mediated knockdown of OCT4 in NCCIT cells. (a) The abundance of OCT4 and Cripto-1 mRNA transcripts was measured using qRT-PCR relative to those of control transfectants. b-actin was used as an internal control for normalization of cDNA content. Data represent the means and SD from three independent experiments performed in duplicate. **P < 0.01. (b) Western blotting of OCT4 and Cripto-1 protein expression by shRNA-mediated knockdown of OCT4 in NCCIT cells using anti-OCT4 and anti-Cripto-1 antibodies. b-actin was used as an internal control for normalization of total protein content. The blots were quantitated using densitometry with the ImageJ software program. **P < 0.01.
Cripto-1 minimal promoter contains a putative OCT4-binding site and is mediated by two transactivation domains
To identify putative OCT4-binding site(s) in the Cripto-1 minimal promoter, we analyzed the consensus sequences using the TFSEARCH database (http://mb s.cbrc.jp/research/db/TFSEARCH.html) and found a putative-binding site ( (Fig. 5A) . To validate the putative-binding site, the core sequence was replaced with the SacI restriction sequence to generate a mutant construct (À100*-Luc). The constructs (À100-Luc and À100*-Luc) were cotransfected with the OCT4 expression vector in NCCIT cells. OCT4 significantly induced the Cripto-1 minimal promoter (À100-Luc) activity in a dose-dependent manner, whereas the transcriptional activity of the mutant construct (À100*-Luc) was not activated even in the presence of OCT4 (Fig. 5B) . These results suggest that OCT4 activates Cripto-1 transcriptional activity via the putative OCT4-binding site within the Cripto-1 minimal promoter.
To confirm whether the OCT4-induced transcriptional activity of the Cripto-1 minimal promoter is specific and mediated by its transactivation domains, we used the deletion constructs containing either one of the transactivation domains spanning the DBD because OCT4 contains two proline-rich transactivation domains within the NTD and CTD [30] . To examine the functional effect of the OCT4 transactivation domains, each construct was cotransfected with the Cripto-1 minimal promoter-reporter vector (À100-Luc) into HEK293T cells. Either NTD or CTD was independently capable of modulating the transcriptional activity of the Cripto-1 minimal promoter. However, the NTD seems to be sufficient to fully activate the transcriptional activity, whereas the CTD was less active compared to the OCT4 FL (Fig. 5C ). These results indicate that both the NTD and CTD of OCT4 mediate transcriptional activation of the Cripto-1 promoter.
OCT4 interacts with the putative OCT4-binding element within the Cripto-1 minimal promoter in vitro and in vivo
To identify whether OCT4 can directly interact with the region containing the putative OCT4-binding site, we performed EMSA and ChIP assays (Fig. 6 ). For EMSA, in vitro transcribed/translated OCT4 protein expression was confirmed by western blot, and the biotin-labeled OCT4-binding site probes (WT and mutant) were prepared using the biotin-labeling kit. As seen in Fig. 6A , the protein-DNA complex is clearly observed in the WT probe (lane 1), whereas the binding affinities substantially decreased in mutant probe or WT competitor (lane 2 and 3). In addition, a supershifted band of protein-DNA complex was clearly observed with the incubation of anti-OCT4 antibody (lane 4), but not with the control IgG antibody (lane 5), indicating the OCT4 specifically binds to the putative OCT4-binding site in an in vitro binding assay.
Then, to confirm whether OCT4 interacts with the minimal promoter region containing the putative OCT4 site in a native context, chromatin of undifferentiated NCCIT cells was subjected to ChIP assay with an anti-OCT4 antibody and amplified by realtime PCR using Cripto-1 promoter-specific primers. Three pairs of primers were used to amplify the region (À74 to +42 depicted as b) spanning the putative-binding site and two other sites (À2713 to À2452 depicted as a and +1378 to +1608 depicted as c) as negative controls to validate OCT4-specific recruitment. Region b (À74 to +42), which contains the putative OCT4-binding site, was significantly enriched compared with the other two regions (Fig. 6B ). These results demonstrate that OCT4 directly binds to the putative OCT4-binding site within the Cripto-1 minimal promoter to upregulate the Cripto-1 transcriptional activity in the native NCCIT cell context.
Discussion
A previous study [23] using the EC cell line NTERA2/ D1 showed that Cripto-1 is heterogeneously expressed in human EC cells, and the subpopulation of cells highly expressing Cripto-1 exhibits a more undifferentiated phenotype with high expression of OCT4 and NANOG. Cripto-1 expression was combinationally regulated by a Smad2/3-dependent endogenous signaling pathway that can be activated by Activin or Nodal and by the ES cell-related transcription factors NANOG and OCT4. However, siRNA-or shRNAmediated knockdown of Cripto-1 did not affect the expression of OCT4 or NANOG, suggesting that endogenous Activin, TGF-b, or Cripto-1-independent signaling may be involved in the maintenance of Fig. 4 . The effect of OCT4 on the transcriptional activities of serial Cripto-1 promoter deletion mutants. Schematic diagram of serial deletion mutants of the Cripto-1 promoter (À3320-Luc, À2595-Luc, À2104-Luc, À1718-Luc, À1048-Luc, À500-Luc, and À100-Luc). Each construct was cotransfected with the OCT4 expression vector or empty vector into NCCIT cells. Transcriptional activity was assessed by luciferase activity relative to the expression of the pGL3-basic vector as a negative control. Data represent the means and SD from three independent experiments performed in duplicate. **P < 0.01.
OCT4 and NANOG expression in this subpopulation with high expression of Cripto-1. In another study [28] , although a subpopulation with high expression of Cripto-1 purified from human carcinoma cells also expressed higher levels of the important stemness-related transcription factors SOX2, OCT4, and NANOG, suppression of Cripto-1 expression significantly reduced the expression of these factors, suggesting that here Cripto-1 may also play a role in tumorigenicity of stem cells. In this study, we investigated the molecular details of Cripto-1 promoter activity regulated by OCT4 in pluripotent human EC NCCIT cells.
RA, important for the regulation of many cellular processes, induces multilineage differentiation and reduces tumorigenicity of EC cells [34, 35] . Here, we demonstrated that Cripto-1 and OCT4 expression is downregulated during RA-mediated differentiation. In addition, expression of endogenous Cripto-1 was significantly increased by overexpression of OCT4 and decreased by OCT4 shRNA-mediated knockdown, suggesting that OCT4 may affect Cripto-1 expression in NCCIT cells (Figs 1 and 2) . RNA interferencemediated suppression of OCT4 in mouse and human ES cells suggested that Cripto-1 is a direct target of OCT4 [36, 37] . Moreover, genome-wide ChIP analysis in mouse ES cells identified OCT4-and NANOGbinding sites within the Cripto-1 promoter region [36] . Therefore, we have further dissected the human Cripto-1 promoter region to identify OCT4-binding site(s).
Cripto-1 gene expression is regulated through cross talk of the Nodal/Cripto-1 signaling pathway with Wnt, Notch, hypoxia, OCT4, and NANOG signaling pathways, suggesting that Cripto-1 is a critical component in both mouse and human ES cells, and that uncontrolled activation of embryonic signaling pathways might lead to transformation and tumorigenicity [38] . Several factors have been studied in the regulation of Cripto-1 expression. The canonical Wnt signaling pathway directly regulates transcriptional regulation of Cripto-1 through an enhancer element containing three tandem TCF/LEF-binding sites within the Cripto-1 gene [39] . Two transforming growth factor b (TGF-b) family members differentially regulate Cripto-1 promoter activity. TGF-b1 upregulates and bone morphogenic protein (BMP)-4 downregulates activity in embryonal and colon cancer cells. Moreover, three Smad binding elements (SBEs) were identified in the Cripto-1 gene. The most distal SBE (SBE1) interacts with SMAD4 and is critical in regulating the responsiveness of the Cripto-1 promoter activity to TGF-b1 and BMP-4 [22] . In addition, under hypoxia, transcription factor hypoxia-inducible factor1a enhances Cripto-1 expression by binding to hypoxia Schematic diagram of the locations of Cripto-1 promoter-specific primer pairs corresponding to positions À2713 to À2452 (a, negative control), À74 to +42 (b, putative OCT4-binding site), and +1378 to +1608 (c, negative control). Bottom panel: Enrichment of OCT4-bound complex on the Cripto-1 minimal promoter region was verified using real-time PCR with Cripto-1 promoter-specific primers. The region b (À74 to +42) of chromatin, which contains the putative OCT4-binding site, was significantly enriched compared to the other two regions (a and c). *P < 0.05.
responsive element-1 within the promoter region in mouse ES and NCCIT cells [40] . Cripto-1 expression in NTERA-2 cells is positively regulated by liver receptor homolog-1 through direct binding to a direct repeat 0 element within the Cripto-1 promoter, whereas germ cell nuclear factor strongly suppresses Cripto-1 expression in these cells [41, 42] . Moreover, the transcription factor Snail, a mediator of epithelial to mesenchymal transition and cell cycle, represses the Cripto-1 gene by direct interaction with the Snail-binding site within the Cripto-1 promoter region, suggesting a novel regulatory mechanism of cell fate decision and tumorigenicity [43] . Here, we demonstrated that dose-dependent overexpression of OCT4 significantly activates Cripto-1 transcriptional activity in both pluripotent EC and nonpluripotent HEK293T cells, suggesting that OCT4 acts as a potent activator in Cripto-1 expression (Fig. 3) . Then, we further dissected the Cripto-1 promoter using serial deletion mutant constructs and overexpression of OCT4 (Fig. 4) . The transcriptional activity of one construct (À500-Luc) was substantially decreased, whereas the activity of another construct (À100-Luc) partially recovered, supporting the previous studies that the negative cis-acting elements are present in this proximal region [41] [42] [43] . Moreover, OCT4 directly binds to the Cripto-1 proximal promoter region as assessed by ChIP assay [23] . We further characterized the OCT4-binding site (
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) within the Cripto-1 minimal promoter region (À100 to À1, relative from the translational start site) by site-directed mutagenesis and binding assays in vivo as well as in vitro (Figs 5  and 6 ). ChIP analysis revealed that the OCT4-and NANOG-binding sites seem to be near one another in the proximal region of the Cripto-1 promoter [23] . The possibility of their interaction and co-occupation should be further investigated to better understand the regulatory mechanisms involving Cripto-1, OCT4, and NANOG. Taken together, our study demonstrates that OCT4 activates Cripto-1 transcription by directly binding to the putative OCT4-binding site within the Cripto-1 minimal promoter region, which may be sufficient for OCT4-mediated Cripto-1 expression in embryonic carcinoma NCCIT cells and may provide an understanding of OCT4-mediated Cripto-1 expression regulatory mechanisms in stem cell-derived tumorigenesis as well as in pluripotency.
